PATENT CLAIM ANALYSIS

Application Number: 15761725
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["514", "017800"]

Abstract:
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and/or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnostic tools.

Claim (Index 17):
An agent which inhibits Kallikrein-8, wherein the agent is bound to a compound which is able to transport the agent across the blood-brain barrier,\n preferably wherein the agent is bound to the compound covalently or non-covalently, and/or in from of a fusion protein, conjugate, complex, liposome or nanoparticle, more preferably wherein the agent is bound to an antibody which specifically binds to the Transferrin receptor (Tfr) or a functionally active part thereof or an antibody mimetic thereof, even more preferably wherein the agent is a protein, preferably an antibody or functionally active part thereof or an antibody mimetic.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 90.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12157664', '13393220', '14324289', '13701758', '11185907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7778615276753149
- 35 USC 102 Novelty (BERT): 0.5238339588538821
- Combined Prediction Score: 0.7524587707931717
- Mean Citation Score: 308.592442
- Max Citation Score: 328.3323
- Similarity Product: 240.72637772197723

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test